NO20071127L - Triazoloftalaziner - Google Patents

Triazoloftalaziner

Info

Publication number
NO20071127L
NO20071127L NO20071127A NO20071127A NO20071127L NO 20071127 L NO20071127 L NO 20071127L NO 20071127 A NO20071127 A NO 20071127A NO 20071127 A NO20071127 A NO 20071127A NO 20071127 L NO20071127 L NO 20071127L
Authority
NO
Norway
Prior art keywords
triazoloftalaziner
meanings
compounds
formula
given
Prior art date
Application number
NO20071127A
Other languages
English (en)
Norwegian (no)
Inventor
Beate Schmidt
Hans-Peter Kley
Steffen Weinbrenner
Dieter Flockererzi
Raimund Kuelzer
Hermann Tenor
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20071127L publication Critical patent/NO20071127L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO20071127A 2004-09-02 2007-02-28 Triazoloftalaziner NO20071127L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104221 2004-09-02
PCT/EP2005/054266 WO2006024640A2 (en) 2004-09-02 2005-08-31 Triazolophthalazines

Publications (1)

Publication Number Publication Date
NO20071127L true NO20071127L (no) 2007-02-28

Family

ID=34929521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071127A NO20071127L (no) 2004-09-02 2007-02-28 Triazoloftalaziner

Country Status (17)

Country Link
US (2) US7851472B2 (https=)
EP (1) EP1791543B1 (https=)
JP (1) JP5140427B2 (https=)
KR (1) KR101368093B1 (https=)
CN (1) CN101133057B (https=)
AT (1) ATE471324T1 (https=)
AU (1) AU2005279221C9 (https=)
BR (1) BRPI0514586A (https=)
CA (1) CA2578368C (https=)
DE (1) DE602005021894D1 (https=)
EA (1) EA014324B1 (https=)
ES (1) ES2347337T3 (https=)
IL (1) IL181271A (https=)
NO (1) NO20071127L (https=)
NZ (1) NZ553160A (https=)
WO (1) WO2006024640A2 (https=)
ZA (1) ZA200701137B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874775B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
BRPI0606379A2 (pt) * 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
DK3134413T3 (da) 2014-04-23 2019-10-14 Dart Neuroscience Cayman Ltd Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
WO2016179059A1 (en) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
AU2018371216B2 (en) * 2017-11-23 2024-09-19 Oslo University Hospital Hf Treatment of tachycardia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81350C (fi) * 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
RU2156252C2 (ru) * 1994-09-16 2000-09-20 Такеда Кемикал Индастриз, Лтд. Триазолопиридазины, способ их получения, фармацевтические композиции на их основе и способ лечения
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
ES2194205T3 (es) * 1996-07-25 2003-11-16 Merck Sharp & Dohme Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.
EP0986562B1 (en) 1997-05-08 2002-08-07 MERCK SHARP & DOHME LTD. Substituted 1,2,4-triazolo 3,4-a]phthalazine derivatives as gaba alpha 5 ligands
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
GB0028583D0 (en) * 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
WO2002083140A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
BRPI0606379A2 (pt) * 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
EP1874775B1 (en) * 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors

Also Published As

Publication number Publication date
BRPI0514586A (pt) 2008-06-17
EA200700537A1 (ru) 2007-10-26
ZA200701137B (en) 2008-11-26
HK1115590A1 (en) 2008-12-05
AU2005279221B2 (en) 2011-10-13
CN101133057A (zh) 2008-02-27
IL181271A (en) 2013-11-28
IL181271A0 (en) 2007-07-04
EP1791543B1 (en) 2010-06-16
US7851472B2 (en) 2010-12-14
EA014324B1 (ru) 2010-10-29
CN101133057B (zh) 2011-03-09
KR101368093B1 (ko) 2014-03-14
DE602005021894D1 (de) 2010-07-29
WO2006024640A2 (en) 2006-03-09
AU2005279221A1 (en) 2006-03-09
NZ553160A (en) 2010-08-27
US20090005372A1 (en) 2009-01-01
KR20070047834A (ko) 2007-05-07
ATE471324T1 (de) 2010-07-15
AU2005279221C1 (en) 2012-05-24
EP1791543A2 (en) 2007-06-06
CA2578368A1 (en) 2006-03-09
JP5140427B2 (ja) 2013-02-06
WO2006024640A3 (en) 2007-06-07
AU2005279221C9 (en) 2012-08-23
ES2347337T3 (es) 2010-10-28
JP2008511586A (ja) 2008-04-17
CA2578368C (en) 2013-07-02
US20100286140A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
NO20071127L (no) Triazoloftalaziner
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA200701840A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
DK1761520T3 (da) Kinaseinhibitorer
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200702584A1 (ru) Спиробензимидазолы как ингибиторы секреции соляной кислоты
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
ATE461189T1 (de) Neue 6-pyridylphenanthridine
DE602004009313D1 (de) Organosiliziumverbindungen und deren verwendung
EA200701366A1 (ru) Кислородсодержащие аннелированные фенилпиперазин- и фенилдиазепанкарбоксамиды

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

FC2A Withdrawal, rejection or dismissal of laid open patent application